u/ederman7

I've been digging into Dyadic International (NASDAQ: DYAI) and think it deserves a closer look from investors interested in biotech infrastructure rather than traditional drug-development companies.

What caught my attention is that DYAI isn't developing a single drug and hoping for FDA approval. Instead, they're building a manufacturing platform (the C1 protein production technology) that could potentially help companies produce biologics, vaccines, antibodies, enzymes, and recombinant proteins faster and at a lower cost.

A few things stood out:

• Platform technology rather than a single-product biotech story

• Existing commercial partnerships and revenue-generating products

• Collaborations involving organizations such as Scripps Research and initiatives supported by global health organizations

• Exposure to multiple industries including vaccines, biologics, cell culture media, animal health, food tech, and industrial enzymes

• Potential beneficiary of the AI revolution in drug discovery

One of the biggest bottlenecks in biotech today isn't necessarily discovering new proteins or antibodies—it's producing them efficiently at scale. As AI accelerates drug and protein discovery, manufacturing capacity could become increasingly important.

The bull case is that DYAI becomes an enabling technology provider across multiple biologics markets rather than relying on the success of a single therapeutic product.

Obviously, it's still a small-cap biotech and comes with all the risks that go along with that, but I think it's a more interesting story than many of the binary biotech names out there.

Curious if anyone else has done due diligence on DYAI or has thoughts on the C1 platform and its long-term commercial potential.

Not financial advice. Do your own research.